Lumicell Inc. announced the presentation of clinical data from its ongoing Phase 2 breast cancer trial with the LUM System, which integrates the immuno- and cancer-targeted optical agent LUM015, the Lumicell handheld imaging device and decision software to detect cancer cells in real-time during surgery.

Lumicell Inc. provided an update on the company’s development strategy for its LUM system pipeline including plans to initiate its pivotal trial in breast cancer as well as expansion of its clinical studies in four other solid tumor cancers.